<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563794</url>
  </required_header>
  <id_info>
    <org_study_id>CSII vs CSII+DPP-4 inhibitor</org_study_id>
    <nct_id>NCT03563794</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes</brief_title>
  <official_title>Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Xiamen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized, controlled clinical trial investigate the efficacy and safety of vildagliptin
      added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">June 10, 2018</start_date>
  <completion_date type="Anticipated">December 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood glucose</measure>
    <time_frame>7 days</time_frame>
    <description>changes from baseline in FPG and 2hPBG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hypoglycemia</measure>
    <time_frame>7 days</time_frame>
    <description>frequancy of hypoglycemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>T2DM</condition>
  <arm_group>
    <arm_group_label>CSII(insulin Lispro)+Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSII(insulin Lispro)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII+Vildagliptin</intervention_name>
    <description>Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.</description>
    <arm_group_label>CSII(insulin Lispro)+Vildagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII(insulin Lispro)</intervention_name>
    <description>T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.</description>
    <arm_group_label>CSII(insulin Lispro)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2DM

          -  30≤ age≤70 years old

          -  BMI 18.0-28.0 Kg/m2

          -  HbA1c ≥8.5%

          -  Negtive GAD、ICA、IAA

          -  Patients do not use antihyperglycemia drugs

          -  Patients use antihyperglycemia drugs for ≥8 weeks(exclusion of DPP-4 inhibitors and
             GLP-1 receptor agonist)

        Exclusion Criteria:

          -  T1DM,GDM

          -  Congestive heart failure (New York Heart Association Functional Classification III-IV)

          -  ALT or AST&gt; 2 times above normal,GFR ＜50ml/min

          -  Severe infection in the previous 3 months

          -  Severely acute or chronic diabetic complications

          -  Patients who were taking medications,known to affect glycaemic control, such as
             glucocorticoids(aside from antidiabetic medications)

          -  History of pancreatitis

          -  Trauma or patients operating at a scheduled time

          -  Any mental health condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiulin Shi, MD</last_name>
    <phone>13959284763</phone>
    <email>shixiulin2002@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first afilliated hospital of Xiamen university</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xue-jun Li, MD,PHD</last_name>
      <phone>13860451316</phone>
      <email>lixuejue99@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xue-jun Li, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 10, 2018</last_update_submitted>
  <last_update_submitted_qc>June 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

